The train has started moving, with successful applications of this tool by multiple pioneering laboratories addressing biological and structural problems. Proteomics, on the other side, sees ever increasing data volumes, leading to questions as to how to store the data mountain publically, use it and convert it into testable hypotheses. The European Proteomics Association meeting has been complementary

to the American Society for Mass Spectrometry meeting in many ways, also thanks to its more manageable size and the vision of the organizers in inviting some of Europe’s best emerging minds.”
“We describe the case of a 27-year-old woman with a family history of Anderson-Fabry disease (AFD). Urinary sediment presented microhematuria and 0.9 MEK inhibitor side effects g/24 hours proteinuria. The alpha-galactosidase A measurement in fibroblasts showed partial deficit of the enzyme, which was compatible with being a carrier of the illness. Renal biopsy gave evidence

of kidney lesions from Fabry disease. Genetic study revealed mutation C52Y or Cys52Tyr, which has not been previously described and had also been detected in the father of the patient. During follow-up, the presence of hypergammaglobulinemia revealed an underlying HIV disease. She is now Epigenetics inhibitor awaiting enzymatic substitution treatment.”
“The 2nd International Conference on Proteomics & Bioinformatics (Proteomics 2012) Las Vegas, NV, USA, 2-4 July 2012 The 2nd International Conference on Proteomics & Bioinformatics (Proteomics 2012) was a follow-up from the successful 1st conference in Hyderabad, India, in June 2011. This conference was sponsored by the OMICS group. Talks on a variety of proteomic and bioinformatic sciences were presented ranging from computation methods, intracellular organelle proteomics, cellular SBI-0206965 proteomics,

to clinical biofluid/tissue proteomics. This conference provided an excellent avenue for a productive multidisciplinary interaction. Several human diseases, for example, diabetes, malaria, glaucoma, bone disorders and others as well as plant pharmacoproteomics and drug development were included. This report summarizes some of the highlights and prospectives presented at this conference.”
“Evaluation of: Diamond DL, Krasnoselsky AL, Burnum KE et al. Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus-mediated liver disease posttransplantation. Hepatology 56(1), 28-38 (2012). HCV is a major cause of chronic liver disease worldwide and is a formidable therapeutic challenge. Recently, Diamond et al.